Bifogade filer
Lumito initiates pilot project with leading professor in urological cancer research at Lund University
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Lumito AB (publ) (“Lumito” or the “Company”) today announces that the Company is initiating a pilot project in collaboration with Professor Anders Bjartell, senior consultant and Professor of Urological Cancer Research at Lund University. The project aims to evaluate the Company’s technology for improved and earlier detection of lymph node metastases in prostate cancer, which is an area where enhanced analytical sensitivity is of great importance for clinical decision-making.
The pilot project is led by Professor Bjartell, an internationally recognised clinical researcher in prostate cancer, and focuses on identifying very low levels of cancer-related biomarkers in tissue. There is a strong need for improved methods to enable early differentiation between aggressive cancer forms and the large proportion of more indolent tumours. Early and more sensitive detection of metastatic spread is crucial for accurate disease staging. This is important both for monitoring disease progression over time and for evaluating existing treatments as well as developing new ones. However, currently available tissue analysis methods have limited sensitivity in this respect, making the need for improved technologies, such as Lumito’s, particularly significant.
“There is a great need for more sensitive methods to detect microscopic spread of prostate cancer. This pilot study gives us the opportunity to evaluate whether new technology can help identify metastases that might otherwise be missed,” says Anders Bjartell, Professor of Urology at Lund University.
Lumito’s technology platform, SCIZYS, is characterised by its high sensitivity and ability to detect low levels of biomarkers in tissue, making it particularly well suited for this type of application. The collaboration is a clear example of market-driven demand from leading researchers for methods offering higher analytical sensitivity than what is currently standard in clinical practice.
“The fact that an internationally leading researcher such as Anders Bjartell chooses to initiate a project based on our strengths in highly sensitive tissue analysis is a strong validation of the significant potential of the SCIZYS platform. It is a challenging task, detecting very low biomarker levels is complex, but a successful pilot project would truly create visibility and contribute to our ongoing market introduction,” says Sanna Wallenborg, CEO of Lumito.
The project is planned to commence during the first quarter of 2026. Within the scope of the project, Lumito will contribute tissue preparation and scanning, while the research group at Lund University will provide tissue sections as well as relevant primary antibodies.